RHOA and cardiovascular disorder: Considering the treatment in patients with cardiovascular diseases in which the RhoA/ROCK signaling is particularly involved, such as spastic angina [20] and stable angina pectoris [34], the clinical view that intermittent administration of organic nitrates cannot only replace the compromised endothelial NO production without nitrate tolerance but also inhibits the RhoA/ROCK pathway is fairly plausible and attractive.